Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide

Mark Girgis, Christopher Hallemeier, William Blum, Randy Brown, Hsiu San Lin, Hanna Khoury, L. Tim Goodnough, Ravi Vij, Steve Devine, Marita Wehde, Stacey Postma, Aarti Oza, John DiPersio, Douglas Adkins

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We hypothesized that low-dose (550-cGy), single-exposure, high dose rate (30 cGy/ min) total body irradiation (TBI) with cyclophosphamide as conditioning for HLA-compatible unrelated donor (URD) bone marrow transplantation (BMT) would result in donor chimerism (DC) with a low risk for serious organ toxicity and treatment-related mortality (TRM). Twenty-six patients with good risk diagnoses (acute leukemia in first complete remission [CR] and chronic-phase chronic myelogenous leukemia [CML]) and 84 with poor risk diagnoses underwent this regimen and URD BMT. Unsorted marrow nucleated cells were assessed for chimerism using VNTR probes. All DC occurred in 78 (86%) of 91 evaluable patients at 1 or more follow-up points. Graft failure occurred in 7 (7.7%) patients. Fatal organ toxicity occurred in only 2% of patients. TRM rates through 2 years of follow-up were 19% and 42% in those with good and poor risk diagnoses, respectively. Overall and disease-free survival rates in the good risk group were 47% and 40%, respectively, and in the poor risk group they were 25% and 21%, respectively, at a median follow-up for living patients of 850 days (range, 354-1588 days). This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM.

Original languageEnglish (US)
Pages (from-to)3035-3041
Number of pages7
JournalBlood
Volume105
Issue number8
DOIs
StatePublished - Apr 15 2005
Externally publishedYes

Fingerprint

Unrelated Donors
Transplants
Chimerism
Whole-Body Irradiation
Cyclophosphamide
Dosimetry
Bone
Bone Marrow
Irradiation
Bone Marrow Transplantation
Toxicity
Tissue Donors
Mortality
Leukemia, Myeloid, Chronic Phase
Grafts
Disease-Free Survival
Leukemia
Therapeutics
Survival Rate

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. / Girgis, Mark; Hallemeier, Christopher; Blum, William; Brown, Randy; Lin, Hsiu San; Khoury, Hanna; Tim Goodnough, L.; Vij, Ravi; Devine, Steve; Wehde, Marita; Postma, Stacey; Oza, Aarti; DiPersio, John; Adkins, Douglas.

In: Blood, Vol. 105, No. 8, 15.04.2005, p. 3035-3041.

Research output: Contribution to journalArticle

Girgis, M, Hallemeier, C, Blum, W, Brown, R, Lin, HS, Khoury, H, Tim Goodnough, L, Vij, R, Devine, S, Wehde, M, Postma, S, Oza, A, DiPersio, J & Adkins, D 2005, 'Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide', Blood, vol. 105, no. 8, pp. 3035-3041. https://doi.org/10.1182/blood-2003-07-2346
Girgis, Mark ; Hallemeier, Christopher ; Blum, William ; Brown, Randy ; Lin, Hsiu San ; Khoury, Hanna ; Tim Goodnough, L. ; Vij, Ravi ; Devine, Steve ; Wehde, Marita ; Postma, Stacey ; Oza, Aarti ; DiPersio, John ; Adkins, Douglas. / Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. In: Blood. 2005 ; Vol. 105, No. 8. pp. 3035-3041.
@article{2543191adc524bf3b2dc3907da410f53,
title = "Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide",
abstract = "We hypothesized that low-dose (550-cGy), single-exposure, high dose rate (30 cGy/ min) total body irradiation (TBI) with cyclophosphamide as conditioning for HLA-compatible unrelated donor (URD) bone marrow transplantation (BMT) would result in donor chimerism (DC) with a low risk for serious organ toxicity and treatment-related mortality (TRM). Twenty-six patients with good risk diagnoses (acute leukemia in first complete remission [CR] and chronic-phase chronic myelogenous leukemia [CML]) and 84 with poor risk diagnoses underwent this regimen and URD BMT. Unsorted marrow nucleated cells were assessed for chimerism using VNTR probes. All DC occurred in 78 (86{\%}) of 91 evaluable patients at 1 or more follow-up points. Graft failure occurred in 7 (7.7{\%}) patients. Fatal organ toxicity occurred in only 2{\%} of patients. TRM rates through 2 years of follow-up were 19{\%} and 42{\%} in those with good and poor risk diagnoses, respectively. Overall and disease-free survival rates in the good risk group were 47{\%} and 40{\%}, respectively, and in the poor risk group they were 25{\%} and 21{\%}, respectively, at a median follow-up for living patients of 850 days (range, 354-1588 days). This regimen resulted in 100{\%} DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM.",
author = "Mark Girgis and Christopher Hallemeier and William Blum and Randy Brown and Lin, {Hsiu San} and Hanna Khoury and {Tim Goodnough}, L. and Ravi Vij and Steve Devine and Marita Wehde and Stacey Postma and Aarti Oza and John DiPersio and Douglas Adkins",
year = "2005",
month = "4",
day = "15",
doi = "10.1182/blood-2003-07-2346",
language = "English (US)",
volume = "105",
pages = "3035--3041",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide

AU - Girgis, Mark

AU - Hallemeier, Christopher

AU - Blum, William

AU - Brown, Randy

AU - Lin, Hsiu San

AU - Khoury, Hanna

AU - Tim Goodnough, L.

AU - Vij, Ravi

AU - Devine, Steve

AU - Wehde, Marita

AU - Postma, Stacey

AU - Oza, Aarti

AU - DiPersio, John

AU - Adkins, Douglas

PY - 2005/4/15

Y1 - 2005/4/15

N2 - We hypothesized that low-dose (550-cGy), single-exposure, high dose rate (30 cGy/ min) total body irradiation (TBI) with cyclophosphamide as conditioning for HLA-compatible unrelated donor (URD) bone marrow transplantation (BMT) would result in donor chimerism (DC) with a low risk for serious organ toxicity and treatment-related mortality (TRM). Twenty-six patients with good risk diagnoses (acute leukemia in first complete remission [CR] and chronic-phase chronic myelogenous leukemia [CML]) and 84 with poor risk diagnoses underwent this regimen and URD BMT. Unsorted marrow nucleated cells were assessed for chimerism using VNTR probes. All DC occurred in 78 (86%) of 91 evaluable patients at 1 or more follow-up points. Graft failure occurred in 7 (7.7%) patients. Fatal organ toxicity occurred in only 2% of patients. TRM rates through 2 years of follow-up were 19% and 42% in those with good and poor risk diagnoses, respectively. Overall and disease-free survival rates in the good risk group were 47% and 40%, respectively, and in the poor risk group they were 25% and 21%, respectively, at a median follow-up for living patients of 850 days (range, 354-1588 days). This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM.

AB - We hypothesized that low-dose (550-cGy), single-exposure, high dose rate (30 cGy/ min) total body irradiation (TBI) with cyclophosphamide as conditioning for HLA-compatible unrelated donor (URD) bone marrow transplantation (BMT) would result in donor chimerism (DC) with a low risk for serious organ toxicity and treatment-related mortality (TRM). Twenty-six patients with good risk diagnoses (acute leukemia in first complete remission [CR] and chronic-phase chronic myelogenous leukemia [CML]) and 84 with poor risk diagnoses underwent this regimen and URD BMT. Unsorted marrow nucleated cells were assessed for chimerism using VNTR probes. All DC occurred in 78 (86%) of 91 evaluable patients at 1 or more follow-up points. Graft failure occurred in 7 (7.7%) patients. Fatal organ toxicity occurred in only 2% of patients. TRM rates through 2 years of follow-up were 19% and 42% in those with good and poor risk diagnoses, respectively. Overall and disease-free survival rates in the good risk group were 47% and 40%, respectively, and in the poor risk group they were 25% and 21%, respectively, at a median follow-up for living patients of 850 days (range, 354-1588 days). This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM.

UR - http://www.scopus.com/inward/record.url?scp=20144386824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144386824&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-07-2346

DO - 10.1182/blood-2003-07-2346

M3 - Article

C2 - 15126314

AN - SCOPUS:20144386824

VL - 105

SP - 3035

EP - 3041

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -